ORLANDO — In this video from the American Academy of Ophthalmology meeting, Jennifer I. Lim, MD, MBA, discusses durable therapies in retina.
Lim highlighted extension data for Vabysmo (faricimab-svoa, Genentech) in the AVONELLE-X study, Eylea HD (aflibercept 8 mg, Regeneron) in the PULSAR study, Izervay (avacincaptad pegol, Astellas) in the GATHER2 trial and Susvimo (port delivery system with ranibizumab, Genentech) in the Portal study.
“This really shows us that some of the treatments we have available in our toolbox can actually help achieve durability in our patients today,” Lim, of the